EPIRUS Biopharmaceuticals, Inc., a commercial-stage biotechnology company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. Its pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) for the treatment of inflammatory diseases; BOW030, a biosimilar version of Avastin (bevacizumab) to treat various cancers; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. The co...
699 Boylston Street
Boston, MA 02116
Founded in 2011
EPIRUS Biopharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 18 14
EPIRUS Biopharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
EPIRUS Biopharmaceuticals, Inc. Launches its First Product Infimab in India
Dec 2 14
EPIRUS Biopharmaceuticals, Inc. announced the launch of its first product, Infimab (BOW015), the first infliximab biosimilar in India. Infimab, a Remicade (infliximab) biosimilar, is being launched in cooperation with EPIRUS' commercialization partner Ranbaxy Laboratories Limited (Ranbaxy). Infimab will be manufactured by Reliance Life Sciences at a facility in Mumbai.
Epirus Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 10 14
EPIRUS Biopharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of $13,929,000 against $3,026,000 a year ago. Loss before income taxes was $13,935,000 against $4,294,000 a year ago. Net loss was $13,935,000 against $4,278,000 a year ago. Basic and diluted loss per share was $1.28 against $18.05 a year ago.
For the nine months, the company reported loss from operations of $29,100,000 against $10,637,000 a year ago. Loss before income taxes was $31,427,000 against $13,038,000 a year ago. Net loss was $31,445,000 against $13,022,000 a year ago. Basic and diluted loss per share was $8.15 against $55.38 a year ago.